News & Analysis on Clinical Trial Services & Contract Research And Development
Curebase: $40m in Series B funding
By Jenni Spinner
- Last updated on
Patient-centric technology company Curebase has announced securing $40m USD in Series B funding, with investors including Gilead Sciences. The investment funds reportedly will be used to further development of its end-to-end clinical trial execution model, virtual and hybrid site capabilities, and eClinical software platform.
“We are pleased that investors are recognizing that Curebase is more than a software platform,” said company founder and CEO Tom Lemberg. “We are an end-to-end clinical trial company with global capabilities and an extensive site network of virtual and hybrid site staff that provides everything needed to successfully execute a better clinical trial.”